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Abstract
Mild hypoxia is common after stroke and associated with poor long-term outcome. Oxygen supplementation could prevent
hypoxia and improve recovery. A previous study of routine oxygen supplementation showed no significant benefit at 7 and
12 months. This pilot study reports the effects of routine oxygen supplementation for 72 hours on oxygen saturation and
neurological outcomes at 1 week after a stroke.Methods: Patients with a clinical diagnosis of acute stroke were recruited
within 24 h of hospital admission between October 2004 and April 2008. Participants were randomized to oxygen via nasal
cannulae (72 h) or control (room air, oxygen given only if clinically indicated). Clinical outcomes were assessed by research
team members at 1 week. Baseline data for oxygen (n = 148) and control (n = 141) did not differ between groups.
Results: The median (interquartile range) National Institutes of Health Stroke Scale (NIHSS) score for the groups at baseline
was 6 (7) and 5 (7) respectively. The median Nocturnal Oxygen Saturation during treatment was 1.4% (0.3) higher in the
oxygen than in the control group (p,0.001) during the intervention. At 1 week, the median NIHSS score had reduced by 2
(3) in the oxygen and by 1 (2) in the control group. 31% of participants in the oxygen group and 14% in the control group
had an improvement of $4 NIHSS points at 1 week doubling the odds of improvement in the oxygen group (OR: 2.9).
Conclusion: Our data show that routine oxygen supplementation started within 24 hours of hospital admission with acute
stroke led to a small, but statistically significant, improvement in neurological recovery at 1 week. However, the difference in
NIHSS improvement may be due to baseline imbalance in stroke severity between the two groups and needs to be
confirmed in a larger study and linked to longer-term clinical outcome.
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Introduction
Hypoxia is common after acute stroke, affecting up to 63%
of patients at some time after admission [1–4]. Hypoxia may
have significant adverse effects on the ischaemic brain after
stroke. While healthy adults with normal cerebral circulation
can compensate for mild hypoxia by an increase in cerebral
blood flow [5], this is not possible in the already ischaemic
brain after stroke [6–8]. There is a clear association bet-
ween hypoxia, neurological deterioration and mortality after
stroke [4,9,10]. Specialist care on stroke units is effective in
preventing death and disability [11]. Patients on stroke units
are less likely to have hypoxic events [12] and more likely to
receive oxygen than patients on a non-specialized general
ward [13].
Oxygen treatment is not without side effects [14]. It impedes
early mobilization, dries mucous membranes, could lead to upper
and lower airway infection, and may disrupt sleep [15]. There is
evidence from animal models and in vitro studies that oxygen
encourages the formation of toxic free radicals leading to further
damage to the ischaemic brain [16–19], especially during
reperfusion [20]. Oxidative stress has also been implicated in the
activation of cell signalling pathways which lead to apoptosis and
neuronal cell death [21,22] Other experimental studies, however,
suggest that eubaric hyperoxia reduces free radical generation in
the ischaemic and reperfused brain [23–25].
There is only one large (n = 550) quasi-randomized study of
oxygen supplementation for acute stroke, and this suggests that
routine oxygen treatment to unselected stroke patients does not
reduce morbidity and mortality [26]. A more recent, very small
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(n = 16), study of short term high flow oxygen treatment
(45 L/min for 8 hours) after acute stroke showed transient early
improvements in neurological performance and infarct size but no
long-term clinical benefit at 3 months [27]. A meta-analysis
of clinical trials of routine oxygen supplementation for acute
myocardial infarction showed no benefit, and potential harm [28].
In a previous study we have shown that low flow (2 L/min) oxygen
supplementation for 24 hours is well tolerated, raising oxygen
saturation by 2.5% and increasing the proportion of patients with
an oxygen saturation .90% throughout the night from 23% to
59% [29].
The evidence for oxygen treatment after acute stroke from
experimental and clinical studies is conflicting, and, unsurprisingly,
stroke management guidelines differ while based on the same
sparse evidence [30–32]. It is therefore important to provide better
evidence to support clinical decision making.
In this paper we report on a pilot study examining the effects of
routine fixed dose oxygen supplementation at a rate of 2 or 3 L/
min dependent on baseline oxygen saturation for 72 hours on
oxygen saturation and neurological recovery at 1 week.
Methods
The protocol for this trial and supporting CONSORT checklist are
available as supporting information; see Checklist S1 and Protocol S1.
Trial design, setting, and subjects
This is a randomized controlled single blind pilot study of
routine oxygen supplementation after acute stroke. A double blind
study could not be used since medical staff would know the group
allocated due to the presence/absence of nasal cannulae. Patients
were recruited from the University Hospital of North Staffordshire
(UHNS), UK, a large teaching hospital admitting about 800
patients with stroke per year. Depending on bed availability, most
stroke patients are admitted to the acute stroke unit within
24 hours of presentation. Patients with an admission diagnosis of
stroke or possible stroke were identified by a member of the stroke
research group, who checked the medical admissions unit log book
every morning and was contactable by the medical admissions
team for new strokes in the day. Adult patients with a clinical
diagnosis of acute stroke [33] were eligible for inclusion if they
were admitted to UHNS within the preceding 24 hours, able to
give informed consent, or a relative was contactable and willing to
give assent, and if there was no clear indication for or against
oxygen treatment. The final decision as to whether the patient had
a definite clinical need for or contraindication against oxygen
treatment was left to the clinician treating the patient. Reasons for
not including patients in the trial were:
N Recognised indications for oxygen treatment such as oxygen
saturation on air ,90%, acute left ventricular failure, severe
pneumonia, pulmonary emboli, and chronic respiratory failure
treated with long term oxygen at home.
N Recognised contraindications to fixed dose oxygen treatment
(2–3 L/min via nasal cannulae), e.g. type II respiratory failure.
N Stroke was not the patient’s primary clinical diagnosis. Patients
with other serious life-threatening illnesses likely to lead to
death within the next few months were also excluded.
Intervention
Participants were randomized to one of two treatment groups,
the oxygen group and the control group. Participants in the
oxygen group were given oxygen at a flow rate of 2 L/min if
baseline oxygen saturation (SpO2) was greater than 93% or at a
rate of 3 L/min if baseline SpO2 was 93% or less. This dose was
based on the results of earlier studies [29,34] and aimed at keeping
the oxygen saturation within the normal range. Oxygen was
administered via nasal cannulae continuously for 72 hours from
the time of recruitment. Short discontinuation of oxygen treatment
was permitted in mobile patients during trips to the toilet and to
physiotherapy, the time periods for these were not recorded but
understood to be no more than one hour. Participants in the
control group were not given routine oxygen supplementation.
Heart rate, blood pressure, and SpO2 were assessed regularly (at
least three times a day) as part of routine clinical care. Those who
developed indications for oxygen, or needed a higher concentra-
tion of oxygen than the protocol prescribed, were given the
concentration of oxygen they needed by the treating clinician,
irrespective of the treatment group they were in.
Randomization
Due to a protocol change after the first year, two randomisation
methods were used. Randomization for the first 153 participants
into either arm of the study, was via telephone, the researcher rang
the randomization number and declared the intent to randomize.
The operator first allocated the patient the next number in a
computer-generated sequence, then recorded basic clinical data
and on completion disclosed the treatment allocation to the
researcher who would initiate the treatment. Once this sequence
was complete, the patient was included in the trial whether
treatment was subsequently administered or not.
From the second year, 148 participants were randomized, into
either arm, via a computer-based portal operating in a similar
sequence to the telephone system described above. Due to
randomness of the allocations between the systems there was a
small imbalance in numbers to each of the 2 treatment arms; a
total of 155 for oxygen and 146 to control. However, we do not
believe that this has led to the introduction of systematic errors.
Baseline clinical assessment and follow-up
At baseline, details of the medical history were established by
interview and consultation of medical notes. Patients were
examined neurologically and classified as total anterior circulation
syndrome (TAC), partial anterior circulation syndrome (PAC),
lacunar syndrome (LAC) and posterior circulation syndrome
(POC) using the Oxfordshire Community Stroke Project (OCSP)
Classification [35]. Neurological deficit was scored using the
National Institute for Health Stroke Scale (NIHSS) [36] and the
Scandinavian Stroke Scale (SSS) [37]. The NIHSS was included
because it is the most widely used stroke scale and allows
comparisons with other ongoing studies, the SSS was also included
to allow comparison with the oxygen supplementation study by
Ronning and Guldvog [26] For both scales death was recorded as
the worst possible score on the scale (35 for NIHSS and 0 for SSS).
Aetiology was determined by computed tomography of the head
and reported as cerebral infarct or intracerebral haemorrhage.
Haemorrhagic infarcts and scans with non-specific findings
compatible with but not diagnostic of acute cerebral infarction
were recorded as infarcts. Both infarcts and haemorrhages were
included because waiting to confirm the diagnosis of ischaemic
stoke before recruitment would have delayed treatment unneces-
sarily and there is no good reason to suspect that oxygen would
harm patients with intracerebral haemorrhage, or that it is more
effective in that group. Pulse oximetry was performed on the
second night of the intervention. At 1 week the NIHSS was
repeated and indicators for potential adverse effects of oxygen
treatment such as stress (tachycardia and hypertension), behaviour
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disturbance (sedative use), and infection (temperature and
antibiotic use) were recorded.
Pulse oximetry
Oxygen saturation and heart rate were assessed using a Pulsox-
3I pulse oximeter (Konica Minolta). The instrument records SpO2
every second producing a moving average every 5 seconds using
an internal algorithm. Hands were inspected to ensure that the
fingers were warm and well-perfused. Nail varnish was removed
and long fingernails were clipped, where necessary. The pulse
oximeter was attached to the wrist and the sensory probe was fitted
to the index finger. To reduce movement artifacts the hemiparetic
side was used for oximetry [38]. Pulse oximetry was performed
overnight from 21:00 to 09:00 on the second night after re-
cruitment. On completion the recorded, data were downloaded
onto a Personal Computer (PC) using Oximeter Download
Software (Stowood Scientific Instruments, Oxford, UK). The first
5 min of the recording were defined as the baseline awake oxygen
saturation and oxygen desaturation was defined as a 4% fall in
saturation compared to baseline. Readings between 23:00 and
07:00 were taken as nocturnal oxygen saturation. If oximetry was
unsuccessful or incomplete (less than 4 hours) it was repeated on
night 3. Recordings with data for less than 4 h were not included
in the final analysis. Recordings which were shorter than 8 h but
at least 4 h long results for T,90 (the time subjects spent with a
SpO2,90%) was corrected to a notional 8 h period using the
formula: T,90 (in minutes) = (T,90 in minutes/actual
recording time in minutes) x 480. The same corrections were
used for T,80 and T.98.
Ethical approval, trial registration, and consent
The protocol was approved by the North Staffordshire
Research Ethics Committee on 06.10.2004 (ref: 04/Q2604/73).
It is registered in the International Standard Randomized
Controlled Trial Number Register (ISRCTN12362720) and the
European Clinical Trials Database (EudraCT number 2004-
001866-41). Written informed consent was sought from all study
participants. Assent from the next of kin was accepted if the patient
agreed to take part but was unable to give fully informed consent.
Participants who were incompetent at the time of recruitment, but
competent when followed-up at 1 week were asked to confirm
consent. Patients who were recruited to the study by assent and
refused consent at 1 week were withdrawn from the study.
Statistical Analysis
Descriptive statistics and counts were performed using Microsoft
Excel, Microsoft Office XP, Microsoft Corporation, US, and tests
of significance (as detailed in the text) were carried out using SPSS
statistical software version 15.0 (SPSS Inc., Chicago, Illinois, US).
Statistical significance was accepted if the p-value was ,0.05.
Results
Recruitment
Three hundred and one patients were recruited to the study
from October 2004 to April 2008, with a mean recruitment rate of
7 (range 1 to 23) per month; the flow of patients through each
stage of the study is shown in figure 1. The initial clinical diagnosis
of stroke was shown to be incorrect in 6 participants in the oxygen
group and 4 in the control group. After further investigation these
were diagnosed as: brain tumour n= 7, motor neurone disease
n = 1, possible multiple sclerosis n = 1 and no final diagnosis n = 1.
At one week follow-up neurological data were available for 143
(97%) and 133 (92%)in the oxygen and control group respectively.
Oximetry data were available for 98 (66%) participants in the
oxygen group and 100 (71%) participants in the control group.
Reasons for missing data are shown in figure 1.
Baseline demographic and clinical data
Baseline demographic and clinical characteristics, stroke type
and severity, and oxygen saturation at randomization were similar
in the control and oxygen group (table 1).
The mean age of patients included in the study was 72.3 (SD
11.6) years, 137 (47%) were male, 243 (84%) were independent for
activities of daily living before the stroke, and 113 (39%) were
living alone. Concomitant medical problems included ischaemic
heart disease in 71 (25%), congestive cardiac failure in 34 (12%),
atrial fibrillation in 53 (18%), and chronic obstructive pulmonary
disease in 26 (9%) of participants. The majority of patients were
normoxic with a mean oxygen saturation of 96.1% (SD 1.9%,
range 90–100%) at randomization. The mean time from stroke
onset to randomization was 17:12 (SD 8:42) hh:min. Bamford
classification data is included in table 1. The final diagnosis at 1
week was cerebral infarct in 254 (88%), intracerebral haemorrhage
in 23 (8%), subdural haemorrhage in 1 (0.3%), transient ischaemic
attack in 6 (2%), and undetermined (no CT head scan) in 7 (2%).
The median Glasgow Coma Scale score (IQR) was 15 (0) and 15
(0) for the control and oxygen groups respectively. The level of
neurological deficit was assessed by the NIHSS scale; median
scores were 6 (7) and 5 (7) for the oxygen and control group
respectively.
Inclusion was via fully informed consent in 115 (78%)
participants in the oxygen group and 106 (75%) in the control
group and by assent in 33 (22%) participants in the oxygen group
and 35 (25%) in the control group. At the 1 week reassessment,
patients who were included via assent were asked to confirm
consent if they had regained competence. One patient in the
control group and 1 patient in the oxygen group refused consent at
that point and were withdrawn.
Oxygen saturation
Oxygen saturation was assessed 3 times a day during the first
72 hours as part of routine clinical practice. In 48 (32%) patients
in the oxygen group and 52 (47%) patients in the control group
one or more readings showed an SpO2 of less than 90% (p= 0.4,
Chi squared test). Twelve patients (8%) in the oxygen group and
16 patients in the control group (11%) were prescribed oxygen for
clinical indications during the treatment period (p = 0.4 Fisher’s
Exact test).
Pulse oximetry was conducted successfully in 98 patients in the
oxygen group and in 100 controls. All parameters of oxygenation
were significantly better in the oxygen than in the control group
except the time spent with an SpO2 of less than 80% and 90% and
the number of participants who spent more than 1 hour with a
saturation of less than 90%. The median Mean Nocturnal Oxygen
Saturation was 1.3% higher in the treatment group than in
controls (p,0.001, Mann-Whitney U test). A lower proportion of
patients in the oxygen group spent more than 5 min and more
than 30 min with an SpO2 of ,90% during the recording night
(p,0.05, Chi squared test). There was no significant difference in
the proportion of patients who spent more than 60 min with an
SpO2 of less then 90%, or in the time spent with an SpO2 of less
than 80%, since such very severe hypoxia was uncommon, and
would have been treated as soon as identified by the clinical team.
Eighty-nine participants (29%) had no or insufficient oximetry
data for analysis. This equated to missing values of 41 and 48 for
the controls and oxygen group respectively. There was no
significant (p = 0.5, Fischer’s Exact test) difference in the pro-
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portion of patients returning no or insufficient oximety data
between the two groups. Participants who did not complete
oximetry were older than those who completed (74.1 vs. 71.4
years), less likely to have been independent before the stroke (73%
vs. 89%), less likely to have full scores on the GCS verbal response
item (57% vs. 71%), less likely to be able to walk (8% vs. 17%), and
were recruited sooner after stroke onset (15:20 vs. 17:10 hh:mm).
Otherwise there were no significant differences in baseline.
Further information on oxygen saturation is provided in table 2.
Neurological outcome at 1 week
Analysis was by intention to treat. Neurological scores improved
from baseline to 1 week in both groups. At baseline the median
(IQR) NIHSS was 6 (7) in the oxygen and 5 (7) in the control
group. By 1 week the median NIHSS scores (including deaths) had
improved more in the oxygen than in the control group 22 (3) for
oxygen vs. 21 (2) for control, p,0.001 Mann Whitney U-test). A
significant improvement in neurological scores was defined as
reduction of 4 or more points in the NIHSS from baseline to
week 1. The odds ratio (95% CI) for significant improvement with
oxygen supplementation was 2.9 (1.59–5.4). Forty five (31%)
participants showed a significant improvement in neurological
score in the oxygen group compared to 18 (14%) participants in
the control group (table 3). There was no difference in the number
of deaths in both groups (4 in the control and 5 in the oxygen
group, p = 1.0 Fisher’s Exact Test).
Exploratory subgroup analysis
Oxygen treatment might be more effective in older patients with
a history of heart and lung problems, those with lower baseline
oxygen saturation, patients with more severe strokes, or those with
an impaired level of consciousness. It might also be affected by
Figure 1. Consort diagram illustrating the flow of participants through the study. NOK: Next of Kin.
doi:10.1371/journal.pone.0019113.g001
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Table 1. Baseline characteristics of the study population.
Oxygen
(n =148)
Control
(n =141)
Demographic characteristics
Mean Age (years) 73 SD 11.7 71 SD 11.5
Male sex (n,) 65 (44%) 72 (51%)
Prognostic factors
Living alone (n) 61 (41%) 52 (37%)
Independent in basic activities of daily living (n) 122 (82%) 121 (86%)
Normal verbal response (n) 102 (69%) 90 (67%)
Able to lift affected arm (n) 92 (62%) 91 (65%)
Able to walk (n) 29 (14%) 20 (15%)
Concomitant medical problems
Ischaemic heart disease (n) 34 (23%) 37 (26%)
Congestive cardiac failure (n) 16 (11%) 18 (13%)
Atrial fibrillation (n) 34 (23%) 19 (14%)
Chronic obstructive pulmonary disease/asthma (n) 14 (10%) 12 (9%)
Details of the stroke
Mean Time since stroke hh:mm) 17:48 SD 8:5 16:31 SD 8:2
Stroke pathology (n% cerebral infarct) 134 (91) 119 (85)
Glasgow Coma Scale Score (median, IQR) 15 (0) 15 (0)
Scandinavian Stroke Scale Score (median, IQR) 39 (15) 42 (18)
National Institute for Health Stroke Scale (median, range) 6 (7) 5 (7)
Total anterior circulation syndrome (n) 24 (17%) 25 (18%)
Partial anterior circulation syndrome (n) 47 (34%) 46 (34%)
Lacunar syndrome (n,) 58 (42%) 57 (42%)
Posterior circulation syndrome (n) 6 (4%) 6 (4%)
Transient ischaemic attacks or unclassified (n) 4 (3%) 3 (2%)
Other Clinical data
Oxygen saturation at randomization (mean) 96.1% SD 1.9 96.1% SD 2.0
SD= Standard deviation
doi:10.1371/journal.pone.0019113.t001
Table 2. The effect of routine oxygen supplementation on oxygen saturation.
Oxygen
Group
(n =98)
Control
Group
(n =100) p-value
Awake Oxygen Saturation (median, IQR, %) 97.0 (1) 95.9 (1.9) ,0.001a
Mean Nocturnal SpO2 (median, IQR, %) 96.0 (2.7) 94.7 (2.0) ,0.001
a
Difference between SpO2 at randomization and awake SpO2 (median, IQR, %) 0.4 (2.8) 20.4 (3.1) ,0.001
a
Lowest Nocturnal SpO2 (median, IQR, %) 91.0 (6.0) 89.0 (6.0) 0.007
a
ODI 4% (median, IQR) 0.3 (1.4) 0.9 (3.2) 0.005a
Tc,90% (median, IQR, hh:mm) 0 (0:04) 0:02 (0:13) NSa
Tc,80% (median, IQR, mm:ss) 0:0 (0:0) 0:0 (0:0) NSa
Tc.98% (median, IQR, hh:mm) 1:31 (4:55) 0:02 (0:20) ,0.001a
More than 5 min Tc,90% (n,%) 20 (20%) 33 (33%) ,0.05b
More than 30 min Tc,90% (n,%) 8 (8%) 17 (17%) ,0.05b
More than 60 min Tc,90% (n,%) 4 (4%) 5 (5%) NSb
aMann Whitney U-test; bChi-squared test; NS: Not significant; ODI 4%: 4% Oxygen Desaturation Index
doi:10.1371/journal.pone.0019113.t002
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treatment with oxygen before randomization and the aetiology of
the stroke (infarct or haemorrhage). We therefore carried out an
exploratory subgroup analysis to identify subgroups which might
benefit more or less from oxygen treatment. The odds ratios for
significant improvement with oxygen treatment (NIHSS reduction
from baseline of 4 or greater) [39] for each of these subgroups are
shown in figure 2. The study was not powered for subgroup
analysis, but the results suggest that there was no significant
difference in the effect for any of the subgroups. The odds ratio for
NIHSS improvement in intracerebral haemorrhages was below 1
(OR=0.69), but the number of participants in this group was too
small to be reliable and hence the confidence interval was very
wide.
Other outcomes at 1 week
There was no significant difference in the group means for
oxygen and control respectively for highest systolic blood pressure
(167 SD 29 mmHg vs. 167 SD 28 mmHg), highest diastolic
blood pressure (93 SD 19 mmHg vs. 91 SD 15 mmHg), and
heart rate (92 SD 16 BPM vs. 92 SD 19 BPM) during the
72 hours of the treatment period. The highest mean temperature
during the first week was similar in both groups (37.2% SD 0.6
vs. 37.1% SD 0.7 C). There was no difference in the proportion
of patients requiring antibiotics in the first week (n = 27 (18%) vs.
n = 22 (15%) for oxygen and control respectively) or sedative
medications (n = 9 (6%) vs. n = 9 (6%) for oxygen and control
respectively).
Discussion
The main finding of this study is that routine oxygen
supplementation, given for 72 hours at a rate of 2 or 3 L/min,
dependent on baseline oxygen saturation leads, to a small but
statistically significant improvement of neurological recovery at 1
week. The odds of improving by 4 or more NIHSS points at 1
week were doubled in the oxygen group. While statically sig-
nificant the difference in the improvement in NIHSS is small and
may be due to the non-significant baseline imbalance in stroke
severity between the two groups (baseline NIHSS was 1 point
higher in the oxygen than in the control group). The NIHSS is not
designed as an outcome tool, and the relevance of a small change
in NIHSS during the first 7 days on longer-term functional
outcome is unclear.
However, other studies have shown that baseline NIHSS is a
strong predictor of recovery and long-term outcome [40–42].
Reanalysis of data from the TOAST (Trial of Org10172 in Acute
Stroke Treatment) Study showed that a 1-point change in NIHSS
from baseline to 3 months was associated with a doubling of the
odds of a very favourable outcome (Glasgow Outcome Scale Score
of 1 and modified Barthel index.18) at 3 months [43].
Our data contrasts with an earlier study by Ronning and
Guldvog [26] which showed no benefit from routine oxygen
supplementation. This is likely not due to differences in patient
population; those of Ronning and Guldvog are comparable to our
study population (mean age 76, median SSS 42/43 and the
proportion of infarcts 87%/87% in strokes and controls in
the Ronning study). The difference in outcome may be due to:
Different time points of assessment (7 months and 1 year for
Ronning and Guldvog, 1 week in this study), longer duration of
treatment (72 hours in this study, 24 hours in the other) Keep the
same order of comparison e.g Ronning V SOS, a different dose of
oxygen (3 L/min for Ronning vs. 2 L/min in 93% and 3 L/min
in 7% of the oxygen group in this study), or due to poor
compliance with the prescribed treatment (11% in the oxygen
group were not given oxygen for 24 hours and 26% of controls
were prescribed oxygen for clinical indications in the Ronning and
Guldvog study). Additionally, the Ronning and Guldvog study did
not report oxygen saturation before and during treatment. It is
therefore impossible to say whether the observed lack of effect
may have been due to failure to improve oxygen saturation on
treatment, or due to oxygen toxicity and free radical formation in
patients with an oxygen saturation at the higher end of the normal
scale. Subgroup analyses in the Ronning and Guldvog [26] study
suggested that patients with milder strokes may have been harmed
by oxygen. The results of our study do not confirm this, but,
conversely, suggest that both mild and more severe strokes
benefited similarly from oxygen supplementation. Neither our
study nor that of Ronning and Guldvog [26] was sufficiently
powered to support subgroup analysis and the dangers of false
positives are acknowledged [44] therefore differences could have
been due to chance. Nevertheless, the dose of oxygen given (2 L/
min in the majority) and the duration of treatment were different
Table 3. Neurological recovery at one week.
Oxygen
N=148
Controls
N=141 P value
NIHSS at randomisation
Median (min; max) 6 (0; 29) 5 (0; 31) NS
IQR 7 7
NIHSS at week 1
Median (min; max) 2.5 (0; 35) 3 (0; 35) NS
IQR 6* 7**
NIHSS difference between baseline and week 1
Median (min; max) 22 (213; 29) 21 (226; 27) ,0.001a
IQR 3 2
Patients with an NIHSS improvement $4 at week 1
n (%) 45 (31)* 18 (14)** ,0.0001b
There were no data for the one week NIHSS in 5 patients in the oxygen group and 8 patients in the control group thus n= 143* for oxygen and n= 133** for control for
the analysis of difference between baseline and week 1 NIHSS. NS: not significant; aMann Whitney U-test; bChi-squared test.
doi:10.1371/journal.pone.0019113.t003
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in our study than in the Ronning and Guldvog study, and this
could explain the difference in outcomes.
A more recent, but small, study by Singhal et al [27] (n = 16)
supports our findings. They dosed oxygen not just to keep
oxygenation within normal range, but to act pharmacologically as
a therapeutic agent. This was achieved by increasing the arterial
oxygenation above normal (oxygen at a rate of 45 L/min given
over 8 hours). NIHSS scores in the treated group were higher at
4h, 24 h, 1 week and 3 months, but this trend only achieved
statistical significance at 24 h. Magnetic resonance imaging at the
same time points showed improved penumbral salvage in the
oxygen group, which achieved statistical significance at 4 h only. A
larger study is ongoing. Even more intensive oxygen treatment
using hyperbaric oxygenation has been tested in acute stroke
patients. A meta-analysis of 3 randomized controlled trials of
hyperbaric oxygen (n= 106) concluded that the sample was too
small to provide clear guidelines for practice, but that a significant
clinical effect was unlikely [45].
While we aimed to include a representative sample of all stroke
patients admitted to the hospital, the majority of subjects included
had relatively mild strokes. The median NIHSS at baseline in this
study was 6 and 5 in the oxygen and control groups respectively,
while the median NIHSS of patients admitted to the local stroke
unit is about 8 (unpublished data from clinical audit 2008/2009).
The main reason for this is the requirement of informed consent or
assent and the short time between admission and recruitment.
While patients with milder strokes can give informed consent,
those with more severe strokes can only be included if assent from
the next of kin can be gained. By the time subjects are identified
for the study, relatives have usually left hospital and are then
contacted during visiting times or have to travel back in to discuss
the study. Patients with more severe strokes were more likely to
benefit from oxygen in the Ronning and Guldvog study [26] and
under representation of this group in our study is likely to reduce
the level of benefit observed. More importantly, it leaves doubts
about the transferability of the results to more severe strokes, and
may mean that those who are most likely to benefit may not be
given the treatment because of lack of evidence. It is important to
include a wide range of patients in acute stroke studies, and
independent physician consent should be considered in this
situation. Independent physician consent for acute stroke studies
is supported by user group consultations [46,47]. Ten patients
included in the study had to be excluded later because they did not
have a stroke. Most of the excluded patients had brain tumours.
Figure 2. Forest plot of the odds of a 4 point or greater improvement of the National Institute for Health Stroke Scale (NIHSS) score
between randomization and week 1. The figures in the oxygen and control columns are the number of events (NIHSS improvement) followed by
the total number in brackets which comprises events and non-events. The figure shows that the odds of improving with oxygen treatment were
similar in all the subgroups tested. The apparent adverse effect in the haematoma group is not significant, and likely to be due to very small numbers
of patients with improvement at one week in this subgroup (one improved in the oxygen group versus 2 on the control group. COPD: chronic
obstructive pulmonary disease, CCF: congestive cardiac failure, SSS: Scandinavian Stroke Scale, GCS: Glasgow Coma Scale, SpO2: oxygen saturation,
Lag SR: time lag between stroke onset to recruitment.
doi:10.1371/journal.pone.0019113.g002
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Patients were included on the basis of the clinical presentation, and
the final diagnosis was made at 1 week when the result of the head
scan was available. Since the number of exclusions was similar in
both groups, this should not have affected the results.
The results of the overnight pulse oximetry showed that oxygen
supplementation effectively improved all parameters of oxygena-
tion. Mean Nocturnal Oxygen Saturation was 1.3% higher in the
oxygen group than in the control group. In two smaller
preparatory studies we have shown that oxygen supplementation
at a rate of 2 L/min during the day with compliance ensured by
continuous observation raises oxygen saturation by 2% [34] and
that the same dose given overnight and observed intermittently (2
am and 3 am) increases nocturnal oxygen saturation during the
first night after the start of treatment by 2.5%. [29] The differences
between these and the current study are likely to be due to
compliance. Smaller studies allow closer observation and thus
better compliance with treatment. Moreover, oxygen saturation
here was assessed on night 2 rather than immediately after the
start of treatment in the previous studies and this again, may have
allowed lower compliance rates. The results of the present study,
which required no additional observation over and above the
usual routine in acute stroke units, most closely resembles current
clinical practice, and will therefore be directly applicable to usual
clinical care. The need to document and monitor compliance with
oxygen prescription more closely has recently been stressed in the
British Thoracic Society Guidelines for emergency oxygen use,
where it is suggested correct administration of oxygen should be
checked and signed off by the nurse at each drug round (e.g. five
times a day) [48]. It is of note that implementation of this guidance
on stroke units is likely to lead to better compliance and may
improve outcomes further.
Oxygen supplementation is simple, cheap, and applicable even
in the most basic clinical environments. The results of this study
suggest that oxygen given at 2 L/min for 72 h may improve
neurological recovery at 1 week. The results of this pilot study
should be confirmed in a larger fully powered trial, which is now
ongoing (The Stroke Oxygen Study) [49]. The findings have led to
a number of modifications of the Stroke Oxygen Study protocol.
Independent physician consent was included to allow more
patients with severe stroke to be included in the trial. Additional
data collection on oxygen saturation and treatment adherence was
included to document compliance with the allocated trial
treatment. The difference in NIHSS between recruitment and
week one was included as a pre-specified secondary outcome.
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